This episode features an in-depth discussion of the Asian cohort analysis from the AtTEnd/ENGOT-EN7 phase III trial, which evaluated atezolizumab in combination with carboplatin and paclitaxel for advanced or recurrent endometrial carcinoma. While atezolizumab improved progression-free survival in mismatch repair-deficient tumors across both Asian and non-Asian populations, it showed no benefit—and potential harm—in mismatch repair-proficient Asian patients. The analysis also revealed a higher incidence of severe adverse events among Asians receiving atezolizumab. These findings highlight the importance of considering ethnic differences in treatment response and toxicity in future clinical trials.

Ver todos los episodios